Background: Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist bronchodilator currently in Phase III clinical development for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the pharmacodynamics, pharmacokinetics, safety and tolerability of ascending doses of aclidinium bromide in patients with COPD. Methods: This double-blind, randomised, placebo-controlled, crossover study was conducted in patients with moderate to severe COPD (forced expiratory volume in 1 s [FEV 1 ] <65% predicted). Patients were randomly assigned to one of four treatment sequences of aclidinium bromide 100, 300, 900 mg and placebo with a washout period between doses. The primary outcome was area under the FEV 1 curve over the 0e24 h time interval. Results: Seventeen patients with COPD were studied. Mean FEV 1 over 24 h was 1.583 L for placebo, and 1.727 L, 1.793 L and 1.815 L for aclidinium bromide 100, 300 and 900 mg, respectively (p < 0.001 vs. placebo, all doses). Significant changes from baseline in FEV 1 were detected 15 min post-dose for aclidinium bromide 300 and 900 mg, with a peak effect 2 h post-dose (all doses). Aclidinium bromide was undetected in plasma. The majority of adverse events was unrelated to study medication and did not result in discontinuation. Conclusion: Aclidinium bromide 100e900 mg produced sustained bronchodilation over 24 h in patients with COPD. ª a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / r m e d Respiratory Medicine (2010) 104, 865e872
Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease characterised by chronic airflow limitation that is not fully reversible. 1 COPD is highly prevalent 2 and associated with increased morbidity and mortality (mainly related to smoking and aging populations 2 ) as well as reduced quality of life. 3, 4 The Global Burden of Disease Study predicts that COPD, the sixth most common cause of mortality in 1990, will become the third most common cause of mortality worldwide by 2020. 2 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 1 recommend the use of bronchodilators to improve airflow and reduce breathlessness and state that long-acting bronchodilators are more effective and convenient than short-acting bronchodilators. For patients with Stage IIeIV COPD (moderate to very severe COPD), regular treatment with one or more long-acting bronchodilators is recommended. 1 Only three long-acting bronchodilators are available to patients with COPD: the b 2 -agonists formoterol and salmeterol, and the anticholinergic tiotropium bromide. COPD is, therefore, not only a disease with significant morbidity and mortality, but also has limited treatment options. 2, 3 Given the serious nature of COPD, and variability in patient response to medication, there is an important need for additional pharmacological options.
Aclidinium bromide is a novel, long-acting inhaled muscarinic antagonist bronchodilator that is being investigated for maintenance treatment of patients with COPD. Aclidinium bromide was discovered after screening a series of candidates to identify an agent that combined significant long-lasting muscarinic M 3 receptor binding with low systemic availability; characteristics considered necessary to yield compounds with a long duration of clinical effect and low potential for adverse events (AEs). Receptor dissociation studies have demonstrated that aclidinium bromide has a long residence time at the M 3 receptor and a shorter residence time at the M 2 receptor. 5 This may be clinically relevant in patients with COPD since stimulation of presynaptic M 2 receptors serves as a feedback mechanism, inhibiting the release of acetylcholine. 6 M 2 receptors also have a prominent role in cardiac function and consequently blockade of these receptors is not desirable. Additionally, in vitro studies have shown that aclidinium bromide in human plasma is rapidly hydrolysed (half-life of 2.4 min) to two major inactive metabolites. 5 In healthy subjects (n Z 16), a single dose of aclidinium bromide resulted in significant, long-lasting (24-h) protection against methacholine-induced bronchoconstriction. 7 The purpose of this study was to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of single ascending doses of aclidinium bromide (100, 300 or 900 mg) in patients with COPD. The choice of the doses was based on the results obtained in a phase I trial performed by our group in healthy volunteers with 50, 300 and 600 mg and that showed all doses to be safe and well tolerated. As administration of 50 mg had no effect on airway calibre and did not offer bronchoprotection, 100 mg was chosen as the lowest dose for this trial, and 900 mg was chosen as the highest dose. 7 
Methods

Patients
All patients recruited into the study were required to have a diagnosis of moderate to severe COPD according to the American Thoracic Society (ATS) guidelines. 8 Patients with a history or evidence of severe allergy (anaphylaxis, angioneurotic oedema) or of any kind of chronic or seasonal allergy (including asthma, urticaria and allergic rhinitis) were excluded from the study. Patients were men aged between 40 and 80 years with a smoking history of at least 10 pack-years. Their COPD had to be stable and meet the following criteria: forced expiratory volume in 1 s (FEV 1 ) <65% of predicted; a FEV 1 /forced vital capacity (FVC) ratio of <70%; and airway reversibility >12% and 200 mL FEV 1 , 30 min after inhalation of ipratropium bromide 80 mg (Atrovent â MDI, Boehringer Ingelheim GmbH, Ingelheim, Germany). Patients with clinically relevant findings on physical examination, laboratory and electrocardiogram (ECG) parameters performed at screening visit were excluded from the study, as were those with significant disease not related to COPD (including the presence of non-COPD pulmonary disease or having suffered a myocardial infarction or stroke within the preceding 6 months). Patients with common cold or viral infection (in the preceding 4 weeks), or who received any investigational drug one month prior to study entry or took b-blockers or oral steroids, were also excluded. Concomitant COPD medications were withdrawn before the bronchodilator test and each study drug administration according to the following schedule: shortacting bronchodilators at least 8 h prior, long-acting bronchodilators (b 2 -agonists) at least 24 h prior, oral b 2 -agonists at least 18 h prior and xanthines at least 36 h prior. No longacting anticholinergic bronchodilators were available at the time the study was conducted (February 2001eMay 2002). Inhaled corticosteroids were permitted if the dose was stable for at least 4 weeks prior to study entry. Other medications, mainly for diseases concomitant with COPD, were permitted if administered at stable doses for at least 3 months prior to study entry. Inhaled salbutamol via propellant metered dose inhaler was allowed during the trial as rescue medication.
All patients gave their voluntary written informed consent to participate. The study protocol and consent forms were approved by the ethics committees of both participating centres. The study was performed in accordance with the Declaration of Helsinki and ICH GCP guidelines.
Procedures
This was a two-centre, double-blind, randomised, ascending single dose, placebo-controlled, crossover trial. Within 14 days of screening visit, eligible patients were randomly assigned to one of four treatment sequences (i.e. 100, 300, 900 mg or matched placebo) with a washout period of at least one week between doses. This washout period was considered sufficient based on the preclinical profile of aclidinium bromide. Study medication was administered by capsule inhaler (Cyclohaler â , Pharmachemie, Haarlem, The Netherlands). Doses were administered between 8:30 am and 10:00 am under fasting conditions and at similar times in each treatment period. The dose range selected in the study was based on the results of a previous clinical trial performed in healthy volunteers in whom a dose-dependent response was seen for 50e600 mg with no drug-related AEs. 7 To better characterise the aclidinium bromide dose range, 100 mg was selected as the lowest dose. The maximum dose of 900 mg was chosen to help ensure the maximum effect was reached.
Lung function tests were performed at screening, predose, 15, 30, 45, 60 and 90 min, and 2, 4, 6, 8, 10, 12, 24 and 32 h after drug inhalation. The primary outcome measure was area under the normalised concentration time curve (AUC) of FEV 1 over the 24-h time period (FEV 1 AUC [0e24]/24 ). Secondary measures included AUC of FVC, peak expiratory flow (PEF) and forced mean expiratory flow (FEF 25e75% ). Onset of effect, maximal effect (peak), time to maximal effect and mean change in FEV 1 were calculated. FVC onset of effect and mean change were also determined. Lung function tests were performed according to ATS recommendations. 9 At least three measurements were taken at each time point and the highest value was used for the analysis.
Blood samples (5 mL) for pharmacokinetic assessments were collected in heparinised tubes containing the esterase inhibitor phenylmethylsulphonyl fluoride (PMSF) at predose, 5, 15, 30, 60 min, 2, 3, 6, 12 and 24 h after every administration. Aclidinium bromide and its acid and alcohol metabolites were determined by liquid chromatography/ tandem mass spectrometry (LC/MS/MS). The lower limit of quantification (LLOQ) was 0.1 ng/mL for aclidinium bromide and its alcohol metabolite, and 1 ng/mL for the acid metabolite. All analyses were performed at Almirall, Barcelona, Spain.
The safety of aclidinium bromide was assessed by means of physical examination, vital signs (pulse rate and blood pressure), 12-lead ECG, laboratory data (haematology, biochemistry and urinalysis) and AEs. Physical examinations were performed at screening, pre-dose and 24 h post-dose. AEs, vital signs and ECG were recorded at screening, predose, and at regular intervals up to 24 h after every drug administration. Laboratory tests were performed at screening and 24 h after each administration.
Statistical analysis
As this was the first trial of aclidinium bromide in patients with COPD, the number of patients randomised into this study was based on previous preliminary studies with other muscarinic antagonists by Maesen et al. (1993) 10 and O'Connor et al. (1996) . 11 The first of these was a pilot doseescalation study in six subjects and the second investigated the prolonged effect of three doses of tiotropium bromide on methacholine-induced bronchoconstriction in 12 subjects compared with placebo. In the present study, we recruited 16 subjects, plus one additional subject to act as a replacement in case of any withdrawals for reasons other than drug-related AEs or COPD deterioration.
AUCs were calculated for FEV 1 , FVC, PEF and FEF 25e75% for the time interval 0e24 h and normalised using the trapezoidal rule divided by 24. 12 The normalised AUCs for the change from baseline were computed. Statistical analysis was performed using an analysis of variance (ANOVA) model for crossover designs including sequence, patient within sequence period and dose as factors. The dose effect was estimated using the least square means with 95% confidence intervals derived from the ANOVA model. The minimum effective dose was determined when the factor dose was statistically significant at a 0.05. Relative change from baseline in FEV 1 and FVC was analysed using a similar ANOVA model but included time as an additional factor and a time vs. dose interaction term. Change from baseline in FEV 1 and FVC was explored by means of descriptive statistics. For safety and pharmacokinetic parameters, descriptive statistics were generated by treatment and dose when applicable.
Results
A total of 17 male Caucasian patients were included in the study; baseline characteristics are shown in Table 1 . One patient withdrew after the second treatment due to personal reasons and was replaced; the replacement patient completed the last two treatments in the sequence. Five patients received stable doses of inhaled steroids throughout the study.
Single doses of aclidinium bromide significantly increased mean FEV 1 over the 24-h period compared with placebo ( Table 2 ). Statistically significant increases in FEV 1 and FVC AUC (0e24)/24 were seen for all three doses of aclidinium bromide compared with placebo and were seen for both absolute and mean changes from baseline ( Table 2) . Change from baseline in FEV 1 AUC (0e24)/24 is shown in Fig. 1 .
There were no statistically significant differences between any of the doses of aclidinium bromide for either absolute or mean changes from baseline for FEV 1 AUC (0e24)/ 24 (p ! 0.172 and !0.082, respectively) or FVC AUC (0e24)/24 (p ! 0.215 and !0.237, respectively).
Mean change from baseline FEV 1 from 0 to 4 h and from 0 to 32 h, for each dose, is shown in Fig. 2a and b, respectively. All doses of aclidinium bromide achieved a sustained bronchodilator effect for up to 24 h as demonstrated by relative changes from baseline in FEV 1 (6.6% for 100 mg, p Z 0.0191; 14.0% for 300 mg, p < 0.0001; and 9.0% for 900 mg, p Z 0.0076, respectively, vs. placebo at 24 h). In addition, aclidinium bromide 300 mg had a sustained effect for up to 32 h (8% improvement in FEV 1 , p Z 0.0132 vs. placebo). At 24 h, mean changes from baseline in FEV 1 for aclidinium bromide 100, 300 and 900 mg were þ0.030 L, þ0.133 L and þ0.131 L, respectively, compared with À0.028 L for placebo. The sustained 24-h bronchodilator effect of aclidinium bromide was also demonstrated by increases in FVC both in relative terms and absolute values (Fig. 3 ). Statistically significant bronchodilation was observed as early as 15 min post-dose (the earliest time point assessed). Mean increases in FEV 1 from baseline at this time point were 0.122 L for aclidinium bromide 300 mg (relative change Z 9.8%; p Z 0.0024) and 0.178 L for aclidinium bromide 900 mg (relative change Z 8.6%; p Z 0.0084). At the lowest dose, this onset of effect was observed at 30 min with an increase in FEV 1 of 0.133 L (relative change Z 9.4%; p Z 0.0012). Aclidinium bromide 300 and 900 mg significantly increased FVC above baseline within 15 min postdose (p Z 0.0006 and 0.0002, respectively), while aclidinium bromide 100 mg significantly increased FVC at 30 min (p Z 0.0002).
All doses of aclidinium bromide had a time to peak effect of 2 h post-dose, with a relative change from baseline in FEV 1 of 17.2% after aclidinium bromide 100 mg (mean increase Z 0.234 L), 23.3% with aclidinium bromide 300 mg (mean increase Z 0.344 L) and 21.4% with 900 mg (mean increase Z 0.377 L).
Aclidinium bromide and its alcohol metabolite were below the LLOQ (<0.1 ng/mL) in plasma following administration of aclidinium bromide 100, 300 and 900 mg at all kinetic time points. The acid metabolite, which was the main compound circulating in plasma, was detected following administration of aclidinium bromide 900 mg with peak plasma concentrations (C max ) of between 3 and 6 ng/ mL achieved approximately 3 h after dosing (t max ). The acid metabolite was also detected at a limited number of kinetic time points after administration of aclidinium bromide 300 mg achieving peak plasma concentrations close to the LLOQ of 1 ng/mL. Due to the very low plasma concentrations of aclidinium bromide and its metabolites, no pharmacokinetic or statistical analyses were performed. There were no deaths, serious AEs or discontinuations due to AEs reported during the study. A total of 28 treatment-emergent AEs were reported in 11 patients during the study. The majority of AEs were mild (64%) or moderate (36%) in intensity and three-quarters (21/28) were considered to be unrelated to the study drug. Seven of these AEs (25%) were considered possibly related to study drug (headache n Z 6, increased sweating n Z 1). There was no relationship between the incidence or severity of AEs, number of patients reporting an AE and dose. The incidence of AEs summarised by treatment is shown in Table 3 . Single doses of aclidinium bromide did not result in any clinically significant changes in vital signs, physical examinations, laboratory tests or any ECG parameters.
Discussion
The results of this study demonstrate that aclidinium bromide, a novel inhaled muscarinic antagonist bronchodilator, has a significant and long-lasting effect with a fast onset of action in patients with moderate to severe COPD.
Aclidinium bromide (100, 300 and 900 mg) significantly improved pulmonary function as assessed by FEV 1 and FVC. The bronchodilatory effect was sustained for at least 24 h as demonstrated by AUC FEV 1(0e24)/24 , the primary endpoint of the study, and by significant improvements in FEV 1 observed over a 24-h period for all doses of aclidinium bromide. The results of this study are consistent with receptor dissociation studies 5 that provide the rationale for long-lasting bronchodilation, with a residence half-life at the M 3 receptor for aclidinium bromide of approximately 15 h.
Aclidinium bromide 300 and 900 mg produced statistically significant increases in FEV 1 at the earliest time point measured (15 min) . These increases corresponded to a mean increase in FEV 1 of 0.122 L for aclidinium bromide 300 mg and 0.178 L for aclidinium bromide 900 mg. The similar bronchodilatory results seen with aclidinium bromide 300 mg and 900 mg were most likely due to the 300 mg dose being sufficient to block the majority of the M 3 receptors functionally involved in muscle contraction.
The maximal effect of aclidinium bromide was observed at 2 h post-dose, with a corresponding mean peak increase in FEV 1 of 17.2%, 23.3% and 21.4% for aclidinium bromide 100, 300 and 900 mg doses, respectively. This maximal effect of aclidinium bromide is similar to that reported in the baseline ipratropium reversibility test (21.1% after 30 min, Table 1 ). However, it should be noted that bronchial reversibility was assessed with ipratropium 80 mg, a dose 2e4 times that usually administered for the maintenance treatment of COPD. In a one-year study of patients with COPD, a maintenance dose of ipratropium 40 mg improved FEV 1 by approximately 0.23 L (19%) 60 min after the administration of the first dose. 13 The improvement in FEV 1 after aclidinium bromide administration observed in this study is similar to that reported for maintenance doses of tiotropium bromide. In a single-dose study reported by Maesen et al., tiotropium bromide over the range 10e80 mg achieved peak improvements in FEV 1 of 19e26%. 14 Further investigation into the doseeresponse relationship with aclidinium bromide is needed to establish the optimal dose range for clinical use. Recently a phase IIb study was published, with parallel study design. A total of 464 patients with moderate to severe stable COPD were randomised to double-blind, once daily treatment with aclidinium (25, 50, 100, 200 or 400 mg), placebo, or open-label tiotropium (18 mg) for 4 weeks. It is of interest to note that in this study also a sustained 24-h bronchodilation was observed, and that the spirometric results observed for aclidinium 200 and 400 mg administered once daily were similar to those observed with tiotropium 18 mg over the 4 weeks of the study. On the basis of this study aclidinium 200 mg once daily was selected for evaluation in phase III studies. 15 Significant increases in FVC, a surrogate for decreases in lung hyperinflation, suggest that aclidinium bromide may improve dyspnoea, the reason most patients seek medical attention and a major cause of disability and anxiety associated with the disease. No relevant differences in bronchodilation were observed in the five patients who received stable doses of inhaled steroids throughout the study.
Muscarinic receptors exist extensively outside of the airways and lungs, 16 and as systemic exposure to anticholinergics may result in undesirable physiological effects, a key requirement for new inhaled anticholinergics is minimal systemic exposure. The low concentration of aclidinium bromide in plasma observed in this study is consistent with earlier in vitro data showing that aclidinium bromide is rapidly hydrolysed to inactive metabolites in human plasma. 5 Consistent with this very low and transient systemic exposure, aclidinium bromide was well tolerated and no patients withdrew due to an AE. Only seven AEs were considered to be possibly related to study treatment. There were no adverse effects commonly associated with anticholinergic muscarinic receptor drugs observed in this study (e.g. dry mouth, constipation, urinary retention and blurred vision), which is consistent with the low systemic availability of aclidinium bromide. The lack of anticholinergic effects with single doses of aclidinium bromide is consistent with the findings of single-dose studies of tiotropium bromide. 10 However, evidence of systemic anticholinergic effects has been reported with multiple dosing of tiotropium bromide. 17, 18 Of further note, single doses of aclidinium bromide had no clinical effect on ECG parameters.
This study was performed in a small group of male patients with known airway reversibility to ipratropium. This inclusion criterion was selected to ensure that aclidinium bromide was being evaluated in patients responsive to inhaled muscarinic antagonist therapy, rather than investigating the efficacy of aclidinium bromide in patients non-responsive to muscarinic antagonists. Recent ATS/European Respiratory Society (ERS) guidelines on outcomes in clinical studies conducted with patients diagnosed with COPD 19 have suggested that in the assessment of the reversibility of airway obstruction, a negative response to a single administration of a bronchodilator should not be used to determine the need for long-term bronchodilator treatment. The inclusion criteria used in this study with respect to airway reversibility are considered to be appropriate for the purpose of this early Phase II clinical study, i.e. the assessment of pharmacodynamics, pharmacokinetics, safety and tolerability of single ascending doses of aclidinium bromide. The results presented here need to be confirmed in larger studies in patients representative of the wider COPD population.
In summary, single doses of inhaled aclidinium bromide had a significant, long-acting bronchodilatory effect with an early onset of action in patients with COPD. The low systemic availability of aclidinium bromide may account for the good tolerability observed in this study. The full therapeutic potential and safety profile of this long-acting bronchodilator requires further assessment. Findings of this study show the potential for aclidinium bromide as a longacting, maintenance treatment for COPD and may provide an important additional therapeutic option for patients with COPD.
